tm logo
CTRS
Dead/Cancelled
CANCELLED – SECTION 71

on 18 Feb 2022

Last Applicant/ Owned by

63 rue de l'Est

F-92100 BOULOGNE BILLANCOURT

FR

Serial Number

79150591 filed on 10th Apr 2014

Registration Number

4783860 registered on 04th Aug 2015

in the Principal Register

Correspondent Address

M. Scott Alprin

M. Scott Alprin

5 Pinehurst Circle, N.W.

Washington DC 20015

Filing Basis

No Filing Basis

Disclaimer

NO DATA

CTRS

Pharmaceutical products for the treatment of biliary insufficiency, cell therapy, inflammatory conditions and disease, hematological conditions and cancer; dietetic substances and foods for medical use, namely, drinks adapted for medical use; antibiotics; capsules for medicines, namely, capsules for treating biliary insufficiency, cell therapy, inflammatory conditions and disease, hematological co Read More

Classification Information


Class [005]
Pharmaceutical Products


Pharmaceutical products for the treatment of biliary insufficiency, cell therapy, inflammatory conditions and disease, hematological conditions and cancer; dietetic substances and foods for medical use, namely, drinks adapted for medical use; antibiotics; capsules for medicines, namely, capsules for treating biliary insufficiency, cell therapy, inflammatory conditions and disease, hematological conditions and cancer; stem cells for medical use; drugs for medical use, namely, pharmaceutical preparations for treating biliary insufficiency, cell therapy, inflammatory conditions and disease, hematological conditions and cancer; medicines for human medicine, namely, pharmaceutical preparations for treating biliary insufficiency, cell therapy, inflammatory conditions and disease, hematological conditions cancer; bacteriological preparations for medical purposes; biological preparations for medical use, namely, biological preparations for treating biliary insufficiency, cell therapy, inflammatory conditions and disease, hematological conditions and cancer; chemical preparations for medical or pharmaceutical use, namely, for treating biliary insufficiency, cell therapy, inflammatory conditions and disease, hematology and cancer; diagnostic products for medical use, namely, medical diagnostic reagents

Class [042]
Computer & Software Services & Scientific Services


Medical services featuring evaluations, estimates and research in the field of science; research and development in the field of medicine and biotechnology; research and development for others in the medical and pharmaceutical field; scientific laboratory services in the medical field; scientific research for medical purposes; biological research; bacteriological research; chemical research

Class [044]
Medical, Beauty & Agricultural Services


Medical services related to biliary insufficiency, cell therapy, inflammatory conditions and disease, hematology and cancer; health counseling services related to biliary insufficiency, cell therapy, inflammatory conditions and disease, hematology and cancer; consultancy in the field of pharmaceutical products; medical information; information on pharmaceutical products; medical analysis services relating to the treatment of patients affected by biliary insufficiency, cell therapy, inflammatory conditions and diseases, hematology-related and cancer-related conditions and diseases; medical diagnostic services

Mark Details


Serial Number

No 79150591

Mark Type

No Service Mark

Attorney Docket Number

No 0184001

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
20th Dec 2022TOTAL INVALIDATION PROCESSED BY THE IB
18th Nov 2022TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
18th Nov 2022INVALIDATION PROCESSED
18th Oct 2022TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
18th Feb 2022CANCELLED SECTION 71
04th Aug 2020COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
07th May 2020NEW REPRESENTATIVE AT IB RECEIVED
15th Nov 2019NEW REPRESENTATIVE AT IB RECEIVED
05th Feb 2016FINAL DECISION TRANSACTION PROCESSED BY IB
06th Jan 2016FINAL DISPOSITION NOTICE SENT TO IB